Business Segments Monte Rosa Therapeutics, Inc.
Stocks
GLUE
US61225M1027
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 18.67 USD | +1.97% |
|
+3.04% | +19.07% |
Sales 2025 by Business Segment
Sales 2025 by Geography
Historical Breakdown of Revenue by Business Segments
Net Income: Breakdown by Business Segment
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
Biological Products | |||||||
Biotechnology (Startups) | - | - | - | 75.62M | 124M | ||
Total Assets | 366M | 342M | 304M | 439M | 449M | ||
Interest Expense | - | - | - | - | - | ||
Income Tax Expense | - | - | 338K | 2.57M | -1.1M | ||
CAPEX | -9.73M | -12.91M | -19.04M | -3.99M | -4.7M | ||
EBT | -73.96M | -109M | -135M | -70.13M | -39.72M | ||
D&A | 2.13M | 3.74M | 6.22M | 10.22M | 10.86M | ||
Operating Income | -72.88M | -112M | -143M | -81.11M | -54.21M | ||
Net Income | -73.96M | -109M | -135M | -72.7M | -38.63M |
Geographical Revenue Distribution History
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
United States | - | - | - | 75.62M | 124M | ||
Total Assets | 366M | 342M | 304M | 439M | 449M | ||
Interest Expense | - | - | - | - | - | ||
Income Tax Expense | - | - | 338K | 2.57M | -1.1M | ||
D&A | 2.13M | 3.74M | 6.22M | 10.22M | 10.86M | ||
CAPEX | -9.73M | -12.91M | -19.04M | -3.99M | -4.7M | ||
Net Income | -73.96M | -109M | -135M | -72.7M | -38.63M | ||
EBT | -73.96M | -109M | -135M | -70.13M | -39.72M | ||
Operating Income | -72.88M | -112M | -143M | -81.11M | -54.21M |
- Stock Market
- Stocks
- GLUE Stock
- Financials Monte Rosa Therapeutics, Inc.
- Business Segments
Select your edition
All financial news and data tailored to specific country editions
